Lancet 2002 Dec 21-28;360(9350):2018-25
Hartung HP, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey SP, Krapf H, Zwingers T.
Department of Neurology, Heinrich-Heine-Universitat, Dusseldorf, Germany
Treatment options for patients with secondary progressive multiple sclerosis are few.
Encouraging results in open-label studies prompted this randomised trial of mitoxantrone in such patients.Methods 194 patients with worsening relapsing-remitting or secondary progressive multiple sclerosis were assigned placebo or mitoxantrone (5 mg/m(2) [exploratory group] or 12 mg/m(2) intravenously) every 3 months for 24 months.
Clinical assessments were made every 3 months for 24 months.
The primary endpoint was a multivariate analysis of five clinical measures.
Analyses of mitoxantrone 12 mg/m(2) versus placebo were based on patients who received at least one dose and returned for at least one assessment of efficacy.Findings Of 194 patients enrolled, 188 were able to be assessed at 24 months.
There were no drug-related serious adverse events or evidence of clinically significant cardiac dysfunction.
At 24 months, the mitoxantrone group experienced benefits compared with
the placebo group for the primary outcome (difference 0.30 [95% CI 0.17-0.44];
p<0.0001) and the preplanned univariate analyses of those measures:
change in expanded disability status scale (0.24 [0.04-0.44]; p=0.0194),
change in ambulation index (0.21 [0.02-0.40]; p=0.0306),
adjusted total number of treated relapses (0.38 [0.18-0.59]; p=0.0002),
time to first treated relapse (0.44 [0.20-0.69]; p=0.0004), and
change in standardised neurological status (0.23 [0.03-0.43]; p=0.0268).
Mitoxantrone 12 mg/m(2) was generally well tolerated and reduced progression of disability and clinical exacerbations.
Further studies are needed to identify the patients with these forms of multiple sclerosis who are most likely to respond to therapy, the best treatment protocols, and the frequency of long-term drug-related side-effects.